Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty

3. november 2026 opdateret af: Poznan University of Medical Sciences

Trial Evaluating Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty

his study will test whether giving dexamethasone through a vein can improve pain control after total hip replacement surgery. Dexamethasone is commonly used to reduce nausea and may also help with pain, but it is not clear which dose works best. Patients will be randomly assigned to receive either no dexamethasone, 4 mg, or 8 mg, in addition to standard anesthesia and a nerve block (PENG block). The main goal is to see how long patients go without needing additional pain medication after surgery. The study will also look at pain levels, use of opioid painkillers, nausea and vomiting, blood sugar levels, and possible side effects.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Effective pain control after total hip arthroplasty (THA) remains a key component of perioperative care, as inadequate analgesia may delay mobilization, prolong hospital stay, and increase the need for opioids. Regional anesthesia techniques, such as the pericapsular nerve group (PENG) block, are increasingly used to improve postoperative pain management while preserving motor function.

Dexamethasone administered intravenously is commonly used in perioperative care, primarily for the prevention of postoperative nausea and vomiting. In addition, it has been shown to prolong the duration of analgesia when used as an adjunct to regional anesthesia. However, there is still uncertainty regarding the optimal intravenous dose that provides clinically meaningful analgesic benefit without increasing the risk of adverse effects, particularly hyperglycemia.

Previous studies have typically used doses ranging from 4 mg to 8 mg, but direct comparisons between these doses, as well as comparison with placebo, remain limited in patients undergoing THA. Furthermore, the potential dose-response relationship of intravenous dexamethasone in this specific surgical population has not been clearly established.

This study is designed to address this knowledge gap by evaluating whether intravenous dexamethasone provides additional analgesic benefit in patients undergoing THA with PENG block, and whether higher doses result in improved outcomes compared to lower doses or no dexamethasone. The findings may help optimize perioperative analgesic strategies and support more evidence-based dosing of dexamethasone in orthopedic surgery.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

198

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Małgorzata Reysner, MD PhD
  • Telefonnummer: +48 (61) 8310122
  • E-mail: mreysner@ump.edu.pl

Undersøgelse Kontakt Backup

Studiesteder

      • Poznan, Polen, 62-701
        • Rekruttering
        • Poznan University of Medical Sciences
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 100 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years
  • Scheduled for elective total hip arthroplasty (THA)
  • Planned use of regional anesthesia including PENG block
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Ability to understand the study procedures and provide written informed consent
  • Ability to assess pain using the Numeric Rating Scale (NRS)

Exclusion Criteria:

  • Known hypersensitivity to dexamethasone or any component of the study medication
  • Chronic corticosteroid therapy or use of systemic steroids within 14 days prior to surgery
  • Active systemic infection or sepsis
  • Significant immunosuppression (e.g., chemotherapy, biological therapy)
  • Pregnancy or breastfeeding
  • Severe cognitive impairment or inability to reliably assess pain
  • Uncontrolled diabetes mellitus (e.g., HbA1c > 8.5% or baseline blood glucose > 200 mg/dL)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo (0 mg Intravenous Dexamethasone)

Participants receive placebo (0.9% sodium chloride) administered intravenously in a volume identical to active treatment after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine.

Intravenous administration of 0.9% sodium chloride in a volume identical to active treatment, given after induction of anesthesia.

Andre navne:
  • 0,9% natriumchlorid
Aktiv komparator: Dexamethasone 4 mg Intravenous

Participants receive 4 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine.

Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 4 mg

Andre navne:
  • Dexamethason natriumphosphat
Aktiv komparator: Dexamethasone 8 mg Intravenous

Participants receive 8 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine.

Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 8 mg

Andre navne:
  • Dexamethason natriumphosphat

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to First Rescue Analgesia
Tidsramme: 48 hours after surgery

Time from the end of surgery to the first administration of rescue analgesia (opioid) due to inadequate pain control (Numeric Rating Scale ≥ 4 or patient request).

48 hours after surgery

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Postoperative Pain Intensity
Tidsramme: 6 hours after surgery

Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain)

6 hours after surgery
Postoperative Pain Intensity
Tidsramme: 12 hours after surgery

Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain)

12 hours after surgery
Postoperative Pain Intensity
Tidsramme: 24 hours after surgery

Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain)

24 hours after surgery
Postoperative Pain Intensity
Tidsramme: 48 hours after surgery

Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain)

48 hours after surgery
Opioid Consumption
Tidsramme: 48 hours after surgery

Total opioid consumption converted to morphine milligram equivalents (MME).

48 hours after surgery
Opioid Consumption
Tidsramme: 24 hours after surgery

Total opioid consumption converted to morphine milligram equivalents (MME).

24 hours after surgery
Incidence of Postoperative Nausea and Vomiting (PONV)
Tidsramme: 24 hours after surgery

Occurrence of nausea and/or vomiting and need for antiemetic treatment.

24 hours after surgery
Blood Glucose Levels
Tidsramme: immidietly after surgery (0 hours after surgery)

Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone.

immidietly after surgery (0 hours after surgery)
Blood Glucose Levels
Tidsramme: 6 hours after surgery

Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone.

6 hours after surgery
Blood Glucose Levels
Tidsramme: 12 hours after surgery

Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone.

12 hours after surgery
Blood Glucose Levels
Tidsramme: 24 hours after surgery

Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone.

24 hours after surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Justyna Marszałek-Buko, MD, Poznan University of Medical Sciences

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. maj 2026

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

31. juli 2027

Datoer for studieregistrering

Først indsendt

6. maj 2026

Først indsendt, der opfyldte QC-kriterier

6. maj 2026

Først opslået (Faktiske)

12. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 3/2026

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .